Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia.

ABSTRACT: Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first- or second-line therapies, a small subset is multirefractory. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is a therapeutic option in these cases. We report a case of an acute aortic dissection (AAD) occurring in a patient without traditional cardiovascular risk factors, 3 months after fostamatinib initiation. A 70-year-old woman with a 30-year history of ITP, unresponsive to multiple therapies, was treated with fostamatinib and achieved a complete haematologic response. She presented with sudden chest pain and was diagnosed with Stanford A (DeBakey type 1) AAD requiring emergency surgery. Histological analysis of her aortic tissue showed

SUBMITTER: Dalmas P 

PROVIDER: S-EPMC12648356 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature